Compounded Semaglutide FDA Warning Letters: Criminal & FCA Risk
FDA has finished mapping the compounded GLP-1 market. Prosecutors are now working it. FDA announced 30 warning letters to telehealth companies over compounded semaglutide and tirzepatide marketing on March 3, 2026, then issued 25 more on June 8. One day after the second wave, the Justice Department unsealed an indictment charging a transnational counterfeit Ozempic distribution scheme. The letters built the record. The criminal and False Claims Act phase runs on it.
Overview: Why Compounded GLP-1s Are Now a Federal Enforcement Priority
FDA announced 30 warning letters to telehealth companies on March 3, 2026 for false or misleading claims about compounded GLP-1 products, and issued 25 more on June 8. Combined with the 2025 wave against compounders and manufacturers, the agency has warned well over 100 companies in the GLP-1 supply chain. Every letter is public. Every letter is documented notice.
The criminal cases have started. On June 9, 2026, DOJ unsealed an indictment charging conspiracy, smuggling, and counterfeit drug trafficking in a transnational counterfeit Ozempic scheme, and federal prosecutors in Chicago have charged a nurse with dispensing counterfeit Ozempic that contained no semaglutide. FDCA misdemeanors require no intent, and under the Park doctrine, executives can be convicted on authority alone.
The civil follow-on is predictable from history. Compounded drug False Claims Act cases produced some of DOJ's largest pharmacy recoveries of the last decade, and the telemedicine prosecution template already exists. Compounders and telehealth prescribers with federal program billing, volume-based compensation, or questionnaire-only prescribing carry FCA, Anti-Kickback, and health care fraud exposure that a warning letter response cannot fix.
Semaglutide and tirzepatide became the most commercially valuable prescription drugs in America, and a parallel industry grew up to sell cheaper versions of them. Telehealth platforms advertise compounded semaglutide for a fraction of the branded price. A patient completes a questionnaire, a prescriber the patient never meets approves it, a compounding pharmacy ships a vial. The model scaled to millions of patients while the branded drugs sat on FDA’s shortage list, because federal compounding law treats shortage drugs differently. Then the shortages ended. FDA removed tirzepatide from the shortage list in December 2024 and declared the semaglutide shortage resolved in February 2025. The legal shield that made mass compounding defensible came down. Much of the industry kept selling anyway.
The government’s response has moved in sequence. In September 2025, FDA sent a broad wave of letters to GLP-1 compounders and manufacturers as part of its crackdown on misleading direct-to-consumer drug advertising. On March 3, 2026, FDA announced 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products, noting it had sent more letters over misleading drug ads in six months than in the entire preceding decade. On June 8, it issued 25 more. By May 21, 2026, FDA had logged more than 1,700 adverse events associated with compounded semaglutide and tirzepatide, many tied to dosing errors from multidose vials. The day after the June letters, DOJ unsealed its first transnational counterfeit Ozempic indictment.
The sequence follows a pattern both of this firm’s founders ran from inside the Department of Justice. Regulatory letters map the market and create notice. Criminal cases start at the edges, with counterfeits and smuggling. Then the False Claims Act and health care fraud cases arrive for the domestic operators: the compounding pharmacies, the platforms, and the prescribers. This analysis, part of the firm’s peptide and GLP-1 fraud defense practice, explains each phase and where the defense decisions sit.
The Warning Letters: What FDA Actually Said
The June 8, 2026 letters, posted on FDA’s public warning letter index on June 16, are the most recent and the most instructive. Five of them show the full range of the agency’s theories.
Maximus Health, Inc., d/b/a Maximus received Warning Letter 730095 based on FDA’s review of its website offering compounded semaglutide and tirzepatide products. Trinity HealthCare Supply, LLC, d/b/a altRx, Warning Letter 728236, was cited on the same framework: the products are drugs under 21 U.S.C. § 321(g), they are new drugs under § 321(p) because they are not generally recognized as safe and effective, and the claims about them create a misleading impression of FDA approval. Glow Medispa, LLC, d/b/a Mint Med, Warning Letter 730390, drew the sourcing theory: product images displayed the Mint Med name on the labels, which suggested Mint Med compounded the drugs when it did not. Altru Telehealth, LLC, Warning Letter 728274, was cited for claims including “FDA approved active ingredient,” promises of the “same results” as the approved drugs, and descriptions of an “FDA approved” compounding pharmacy. Momentum Health 360, d/b/a Momentum Health, Warning Letter 728286, combined both theories: its own name on pictured product labels, plus claims comparing its compounded semaglutide and tirzepatide to Ozempic, Wegovy, Mounjaro, and Zepbound.
Two theories carry every letter.
Sameness and Approval Claims
Compounded drugs are not FDA-approved. The agency does not review their safety, effectiveness, or quality before they are sold, and there are no FDA-approved generic versions of semaglutide or tirzepatide. Marketing that calls a compounded product “generic semaglutide,” describes it as identical or equivalent to the branded drugs, borrows the clinical trial results of the approved products, or attaches “FDA approved” language to any part of the product or process creates a false impression of regulatory status. FDA treats that as misbranding under the Federal Food, Drug, and Cosmetic Act, and the products as unapproved new drugs introduced into interstate commerce in violation of 21 U.S.C. § 331 and § 355(a).
Sourcing Misrepresentation
The second theory reaches further. Under 21 C.F.R. § 201.1(h)(2), a person’s name on a drug label without qualification represents that the named person is the sole manufacturer. Telehealth platforms that buy compounded product from third-party pharmacies and market it under their own brand are, in FDA’s view, misrepresenting who made the drug. Nearly every direct-to-consumer GLP-1 platform white-labels its product. FDA has now said, dozens of times in writing, that the practice misbrands the drug. Any platform still doing it after June 2026 is doing it on notice, and notice is what converts a strict-liability misdemeanor into a fraud felony.
The Compounding Statutes Underneath
The marketing letters sit on top of a structural problem. Sections 503A and 503B of the FDCA, codified at 21 U.S.C. § 353a and § 353b, define when compounding is lawful, and both bar compounding drugs that are essentially copies of commercially available approved drugs. The shortage designations suspended that bar. The shortage resolutions restored it. A pharmacy mass-producing standard-dose semaglutide copies in August 2026 needs a patient-specific clinical justification for every prescription, and a lower price is not one. FDA’s separate 2025 and 2026 letters to compounders and outsourcing facilities cite adulteration and insanitary conditions on top of the copying problem. The firm’s pharmacy compounding fraud defense practice addresses both layers.
The Criminal Cases Have Already Started
A warning letter is a civil document. The conduct it describes is not civil-only conduct.
The Counterfeit Ozempic Indictment
On June 9, 2026, one day after the second warning letter wave, DOJ unsealed an indictment in United States v. Roy and Ramancha. The charges: conspiracy, three counts of smuggling, and two counts of selling counterfeit drugs and holding them for sale. The indictment alleges the defendants obtained counterfeit Ozempic from unauthorized sources in China, complete with counterfeit packaging, labeling, and needles designed to pass as authentic Novo Nordisk product, and sold it to distributors in the United States at deep discounts. One allegation deserves particular attention. The scheme allegedly continued after FDA seized counterfeit product in December 2023 and issued a public warning. Conduct that continues past documented government notice is how prosecutors prove intent. The warning letters issued this year build the same record for the domestic industry.
The Individual Prosecutions
The government is not waiting for large targets. The U.S. Attorney’s Office for the Northern District of Illinois charged a registered nurse with one count of distributing misbranded drugs and three counts of dispensing counterfeit drugs, based on sales of counterfeit Ozempic to three individuals. The product carried the Ozempic label. It contained no semaglutide. The case was built by FDA’s Office of Criminal Investigations, the same component that feeds the warning letter program, and it marks the floor of the charging range: a licensed professional, three buyers, four federal counts.
FDCA Exposure for Warning Letter Recipients
The statutes cited in the warning letters are themselves criminal statutes. Under 21 U.S.C. § 333(a)(1), any violation of § 331, including introducing a misbranded or unapproved new drug into interstate commerce, is a misdemeanor punishable by up to one year. No intent element applies. Under the responsible corporate officer doctrine of United States v. Park, 421 U.S. 658 (1975), an executive can be convicted based on authority over the violation, without proof of personal knowledge. Under § 333(a)(2), a violation committed with intent to defraud or mislead is a felony carrying up to three years per count. The intent evidence in these cases is usually already public: the marketing claims FDA quoted, the white-labeled vials, and every sale made after the letter arrived. FDCA counts rarely travel alone. In the GLP-1 supply chain they arrive with wire fraud, smuggling under 18 U.S.C. § 545, and trafficking in counterfeit goods under 18 U.S.C. § 2320.
The scheme allegedly continued even after the FDA seized some of the counterfeit Ozempic and issued a public warning regarding the products.
— DOJ Criminal Division case summary, United States v. Roy and Ramancha (indictment unsealed June 9, 2026)The FCA Follow-On: Why It Is Coming and Who It Reaches
Criminal cases move one defendant at a time. The False Claims Act moves against balance sheets, and DOJ has run this exact play against compounding pharmacies before. The TRICARE compounded cream cases of the last decade produced hundreds of millions of dollars in FCA recoveries, criminal convictions of pharmacy owners and marketers, and a template the Department never retired. The GLP-1 market fits it on three theories.
Theory One: False Claims About the Product
Under 31 U.S.C. § 3729, knowingly submitting a false claim to a federal program carries treble damages plus a per-claim penalty. Claims to Medicare, Medicaid, or TRICARE for compounded GLP-1s that misrepresent the ingredients, the concentration, the compounding pharmacy’s status, or the product’s regulatory posture are candidates. So are claims for related services, including telehealth evaluation codes billed around a prescription pipeline. FDA’s adverse event data, which documents subpotent, superpotent, and contaminated product in the market, hands relators and prosecutors the factual predicate. The warning letters hand them scienter. FCA liability requires knowledge, deliberate ignorance, or reckless disregard, and a public letter from FDA describing a company’s claims as false is evidence of all three for conduct that continued afterward. The letters cut the other way too. Because they are public, they may trigger the FCA public disclosure bar of 31 U.S.C. § 3730(e)(4) against relators whose complaints add nothing to what FDA already published. Expect that bar to be the first motion filed in the qui tam wave.
Theory Two: Medical Necessity and Invalid Prescriptions
The questionnaire model is the exposed flank. A prescription generated from an asynchronous intake form, approved in seconds by a prescriber paid per approval, invites the argument that no valid practitioner-patient relationship existed and the resulting claims were false. DOJ built its national telemedicine takedowns on this theory, charging billions of dollars in schemes involving orthotics, genetic tests, and creams ordered by prescribers who never meaningfully evaluated the patient. The GLP-1 version substitutes a weight-loss questionnaire for the brace order form. The structure the government proves is the same. Drew Bradylyons supervised the strike force that built those cases; the firm’s telemedicine fraud defense practice defends against them.
Theory Three: Kickback Taint
The Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b), is a felony carrying up to 10 years per count, and under § 1320a-7b(g), every claim resulting from a kickback is automatically false under the FCA. Now trace the money in this market. Pharmacies pay platforms per prescription routed to them. Platforms pay prescribers per consult or per script. Marketing affiliates are compensated on prescription volume. Each of those flows, where federal program business is in the mix, is the fact pattern of an AKS count. Cash-pay volume dilutes the exposure but rarely eliminates it, because few platforms and fewer pharmacies have zero federal business, and a single relator with the billing data can establish the mix. Where the business is genuinely all cash, prosecutors substitute wire fraud for the deception of consumers, as the counterfeit cases already show. The firm’s healthcare fraud defense practice covers the AKS and the health care fraud statute, 18 U.S.C. § 1347, that anchor these cases.
Who Is Exposed, and How
Compounding Pharmacies and Outsourcing Facilities
Pharmacies face the full stack: FDCA counts for producing essentially-copy GLP-1s outside the 503A and 503B conditions, adulteration counts where FDA inspections found sterility failures, FCA liability for federal claims, and AKS exposure for volume-based arrangements with platforms. The pharmacy also holds the records every other target needs: prescription volumes, prescriber concentrations, and payment terms. That makes pharmacies both early targets and early witnesses. The order in which a pharmacy engages with FDA, DOJ, and its platform counterparties determines which role it plays.
Telehealth Platforms and Their Executives
Platforms carry the marketing liability the warning letters describe, the sourcing misrepresentation problem on every white-labeled vial, and the kickback exposure built into their prescriber compensation. Their executives carry Park doctrine exposure personally. A misdemeanor FDCA conviction requires no proof the executive knew anything. A felony requires intent to defraud or mislead, and the government will read intent from marketing decisions made after March 3, 2026.
Prescribers
Physicians, nurse practitioners, and physician assistants who write for these platforms are the individual defendants the telemedicine takedowns taught DOJ to charge. The government’s proof in those cases was volume and emptiness: thousands of approvals, seconds per chart, compensation per signature, no follow-up. Prescribers with genuine evaluations, independent judgment, and contemporaneous records can defend. Prescribers who signed what the platform queued cannot, and the platform’s own data will show which kind each prescriber was. GLP-1s are not controlled substances, so trafficking counts and Ryan Haight Act issues are off the table, but health care fraud, wire fraud, and AKS conspiracy do not require a scheduled drug.
Where the Defense Begins
Every matter in this space now runs on three tracks at once: the FDA regulatory track with its 15-day response clock, the civil track where relators and brand manufacturers are already filing, and the criminal track that moves silently until it does not. The central judgment is sequencing. A warning letter response is discoverable. A corrective action plan is an admission if drafted carelessly. A platform’s renegotiation of its pharmacy contract can look like consciousness of guilt or like responsible compliance, depending entirely on how and when it is documented. Companies that treat the letter as a marketing problem and hand it to regulatory counsel alone routinely discover, a year later, that they spent their best facts answering the least dangerous inquiry.
The substantive defenses exist. Statements about active ingredients can be truthful without being approval claims, and the line FDA draws is contestable. Patient-specific compounding under 503A remains lawful, and documented clinical justifications defeat the essentially-a-copy theory prescription by prescription. Medical necessity records, fair-market-value analyses of platform compensation, and the public disclosure bar against recycled qui tam complaints all do work. None of it does work retroactively. The record supporting each defense must exist before the subpoena arrives, and nothing said on the regulatory track can be allowed to give it away.
The Government’s Playbook, From the Inside
The components running this enforcement wave are the components the firm’s founders come from. Scott Armstrong served as Director of DOJ’s Appalachian Regional Prescription Opioid Strike Force, the Department’s dedicated unit for prosecuting medical professionals in prescription drug cases, which charged more than 120 defendants across 10 federal districts, and as an Assistant Chief in the Fraud Section, where he tried sixteen federal jury trials, nine of them healthcare fraud trials, and served as lead counsel in cases totaling over $600 million in false claims. Drew Bradylyons served as an Assistant Chief in DOJ’s Health Care Fraud Unit, supervising the Miami Strike Force that built the telemedicine prosecution model now aimed at GLP-1 platforms, and as Chief of the Financial Crimes and Public Corruption Unit at the U.S. Attorney’s Office for the Eastern District of Virginia, where he supervised parallel civil, criminal, and administrative proceedings involving more than $1 billion in claims. The firm defends compounders, platforms, prescribers, and executives in these matters nationwide.
Frequently Asked Questions: Compounded Semaglutide and GLP-1 Enforcement
Why did the FDA send warning letters to telehealth companies about compounded semaglutide and GLP-1 drugs?
FDA concluded that the companies’ websites made false or misleading claims about compounded GLP-1 products, which are not FDA-approved. On March 3, 2026, FDA announced 30 warning letters, and on June 8, 2026 it issued 25 more, on top of the broader 2025 wave aimed at compounders and manufacturers. Two theories recur. First, sameness claims: describing compounded semaglutide or tirzepatide as generic, identical, or equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound, or borrowing the approved drugs’ clinical trial results. There are no FDA-approved generics of these drugs, and compounded drugs are not reviewed for safety, effectiveness, or quality before sale.
Second, sourcing misrepresentation. Under 21 C.F.R. § 201.1(h)(2), a company’s name on a drug label without qualification represents that it manufactured the product. Platforms that white-label third-party compounded product, as the letters to Mint Med and Momentum Health describe, misbrand the drug in FDA’s view. Recipients have 15 business days to respond, and the letters warn of seizure and injunction without further notice.
Is compounded semaglutide still legal in 2026?
Only within narrow and shrinking limits. Compounded drugs are never FDA-approved, but sections 503A and 503B of the FDCA, 21 U.S.C. § 353a and § 353b, permit compounding under defined conditions, and both restrict compounding drugs that are essentially copies of commercially available approved drugs. During the semaglutide and tirzepatide shortages that restriction was relaxed. FDA removed tirzepatide from the shortage list in December 2024, declared the semaglutide shortage resolved in February 2025, and set enforcement deadlines in spring 2025.
Since then, routine compounding of standard-dose GLP-1 copies has generally fallen outside the statutory shield absent a documented, patient-specific clinical difference. FDA has also signaled its intent to restrict the bulk substances used in large-scale GLP-1 compounding and had logged more than 1,700 adverse events associated with compounded semaglutide and tirzepatide by May 2026. Volume compounding of GLP-1 copies now operates against the statute, the shortage resolutions, and three waves of warning letters. The firm’s pharmacy compounding fraud defense practice covers where the lawful boundaries actually sit.
Can an FDA warning letter lead to criminal charges?
Yes. A warning letter is not a charge, but the conduct it describes is frequently chargeable, and the letter becomes evidence. Under 21 U.S.C. § 333(a)(1), any violation of § 331 is a misdemeanor punishable by up to one year, with no intent requirement. Under United States v. Park, 421 U.S. 658 (1975), executives can be convicted based on their authority over the violation, without proof of personal knowledge. Under § 333(a)(2), a violation committed with intent to defraud or mislead is a felony carrying up to three years per count.
The warning letter supplies the notice. Marketing that continues after a documented FDA warning is marketing done with knowledge, and prosecutors build felony intent from that record. The June 2026 counterfeit Ozempic indictment makes the point: DOJ specifically alleged the scheme continued after FDA’s December 2023 seizure and public warning. The firm’s peptide and GLP-1 fraud defense practice handles the transition from regulatory response to criminal defense, which is where these matters are won or lost.
What criminal charges has DOJ filed for counterfeit Ozempic and semaglutide diversion?
The prosecutions span the supply chain. On June 9, 2026, DOJ unsealed the indictment in United States v. Roy and Ramancha, charging conspiracy, three counts of smuggling, and two counts of selling counterfeit drugs, based on an alleged scheme to distribute counterfeit Ozempic sourced from China with counterfeit packaging, labeling, and needles. Separately, the Northern District of Illinois charged a registered nurse with distributing misbranded drugs and dispensing counterfeit Ozempic that contained no semaglutide.
The charging menu is now visible: counterfeit drug trafficking under 18 U.S.C. § 2320, smuggling under § 545, FDCA misbranding and unapproved new drug counts, and wire fraud for the deception of purchasers. The cases were built by FDA’s Office of Criminal Investigations from website evidence, import records, and adverse event data, the same inputs that generate the warning letters. The distance between a warning letter file and a criminal referral is one prosecutorial decision.
What False Claims Act liability do compounding pharmacies face for compounded GLP-1 drugs?
Three theories dominate. First, product falsity: claims to Medicare, Medicaid, or TRICARE that misrepresent the ingredients, concentration, or regulatory status of a compounded GLP-1 can be false claims under 31 U.S.C. § 3729, carrying treble damages and per-claim penalties. DOJ ran this framework against compounding pharmacies in the TRICARE cream cases and recovered hundreds of millions of dollars. Second, medical necessity: prescriptions generated from questionnaire-only encounters invite the theory that no valid practitioner-patient relationship existed. Third, kickback taint: under 42 U.S.C. § 1320a-7b(g), every claim resulting from an Anti-Kickback violation is automatically false.
Cash-pay volume dilutes but rarely eliminates the exposure, because few pharmacies have zero federal business and a single relator with the billing data can establish the mix. FDA’s warning letters supply relators with falsity and scienter evidence, though their public nature may also trigger the public disclosure bar of 31 U.S.C. § 3730(e)(4) against complaints that add nothing to what FDA published. The firm’s pharmacy compounding fraud defense practice addresses these theories, including the parallel-proceedings problem FCA cases create alongside criminal investigations.
Does the Anti-Kickback Statute apply to telehealth weight loss prescribing?
Yes, wherever federal program business is in the mix. The Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b), prohibits paying or receiving remuneration to induce referrals of federally reimbursable items, and it is a felony carrying up to 10 years per count. The payment flows common in the GLP-1 market track the government’s telemedicine prosecution template: pharmacies paying platforms per routed prescription, platforms paying prescribers per consult or per approval, and marketers compensated on prescription volume. DOJ’s national telemedicine takedowns charged billions of dollars in schemes built on those flows.
The lawful models pay fair market value for actual services, untied to volume, with prescribers exercising documented independent judgment. Where federal program money is genuinely absent, prosecutors substitute wire fraud. The firm’s telemedicine fraud defense and healthcare fraud defense practices analyze these arrangements against the statutory safe harbors, drawing on the founders’ experience supervising and trying the telemedicine cases that created this template.
How long do companies have to respond to an FDA warning letter, and what happens after?
Fifteen business days. The letter demands a written response with corrective actions and documentation, and it warns of legal action without further notice, including seizure under 21 U.S.C. § 334 and injunction under § 332. Several consequences follow regardless of the response. The letter is public and permanent on FDA’s warning letter index. Payment processors, state boards, commercial payors, plaintiffs’ firms, and the brand manufacturers all read it, and Novo Nordisk and Eli Lilly have filed hundreds of civil suits against compounders and sellers.
The letter also fixes the company with documented notice, which is the raw material for felony intent under § 333(a)(2) and for FCA scienter. The response itself is discoverable, and admissions made to close the regulatory matter can surface before a grand jury. The problem is sequencing, not just compliance: what to say to FDA, in what order, while preserving defenses in the criminal and civil matters that may follow. That sequencing judgment is the core of the firm’s peptide and GLP-1 fraud defense work.
Can telehealth doctors and nurse practitioners be prosecuted for prescribing compounded semaglutide?
Yes. Physicians, nurse practitioners, and physician assistants who write for GLP-1 platforms are the individual defendants DOJ’s telemedicine takedowns taught the government to charge. The proof in those cases was volume and emptiness: thousands of approvals, seconds per chart, per-signature compensation, no follow-up. Semaglutide and tirzepatide are not controlled substances, so trafficking counts and Ryan Haight Act issues are off the table, but health care fraud under 18 U.S.C. § 1347, wire fraud, and Anti-Kickback conspiracy do not require a scheduled drug, and platform executives separately carry Park doctrine exposure on the FDCA counts.
The defenses are documentary. Genuine evaluations, independent clinical judgment, declined prescriptions, and contemporaneous records separate practitioners from signature mills, and the platform’s own data will show which each prescriber was. The record that matters is the one that exists before a subpoena arrives. The firm defends prescribers in these matters through its telemedicine fraud defense practice.
Who defends FDA warning letter and compounded GLP-1 investigations?
Armstrong & Bradylyons PLLC defends compounding pharmacies, outsourcing facilities, telehealth platforms, prescribers, and healthcare executives in federal GLP-1, peptide, compounding, and telemedicine investigations nationwide. Scott Armstrong directed DOJ’s Appalachian Regional Prescription Opioid Strike Force, which charged more than 120 defendants across 10 federal districts, served as an Assistant Chief in the Fraud Section, tried sixteen federal jury trials including nine healthcare fraud trials, and was lead counsel in cases totaling over $600 million in false claims. Drew Bradylyons served as an Assistant Chief in the Health Care Fraud Unit, supervising the Miami Strike Force that built the telemedicine prosecution model, and as Chief of the Financial Crimes and Public Corruption Unit at the U.S. Attorney’s Office for the Eastern District of Virginia, supervising parallel proceedings involving more than $1 billion in claims. The firm is based in Washington, D.C. and handles matters in every federal district.
Facing a GLP-1, Compounding, or Telehealth Investigation?
Armstrong & Bradylyons PLLC defends compounders, telehealth platforms, prescribers, and executives in federal investigations involving peptide and GLP-1 fraud, pharmacy compounding fraud, telemedicine fraud, and healthcare fraud and the Anti-Kickback Statute. The firm provides trial-ready defense in parallel FDA, DOJ, and False Claims Act proceedings nationwide.
